Red yeast rice-induced severe rhabdomyolysis complicated by acute kidney injury and respiratory failure: a case report.

IF 3.1 3区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Frontiers in Medicine Pub Date : 2025-08-20 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1634047
Pengmin Zhou, Yucai Hong, Huabo Cai, Xiaoyu Zhou, Shunpeng He, Haotian Zhou, Jie Yang, Pengpeng Chen, Boming Xia, Xiong Lei, Suibi Yang, Zhongheng Zhang
{"title":"Red yeast rice-induced severe rhabdomyolysis complicated by acute kidney injury and respiratory failure: a case report.","authors":"Pengmin Zhou, Yucai Hong, Huabo Cai, Xiaoyu Zhou, Shunpeng He, Haotian Zhou, Jie Yang, Pengpeng Chen, Boming Xia, Xiong Lei, Suibi Yang, Zhongheng Zhang","doi":"10.3389/fmed.2025.1634047","DOIUrl":null,"url":null,"abstract":"<p><p>Red yeast rice (RYR), a commonly used supplement with statin-like properties, is generally considered safe but may cause severe adverse effects such as rhabdomyolysis. We report a rare case of severe RYR-induced rhabdomyolysis complicated by acute kidney injury (AKI) and respiratory failure, with diaphragmatic dysfunction as a key contributing factor. A 78-year-old woman developed progressive proximal muscle weakness, dyspnea, and tea-colored urine after taking RYR (2 g/day) for 1 month. She rapidly progressed to respiratory failure requiring intubation and mechanical ventilation. Laboratory tests showed a peak creatine kinase (CK) of 112,985 U/L, serum myoglobin (>3,000 μg/L), and AKI. Bedside ultrasound demonstrated diaphragmatic dysfunction, while electromyography (EMG) revealed preserved nerve conduction. Myositis-specific and paraneoplastic antibody panels were negative. She received continuous renal replacement therapy (CRRT), plasma exchange (PE), hemoperfusion (HP), and supportive care. During hospitalization, she developed deep vein thrombosis (DVT), pneumonia, and ileus, all of which resolved with treatment. At discharge, she had been weaned from mechanical ventilation and had partially recovered renal and muscle function. At follow-up, she was stable, ambulating, and performing daily functions without symptom recurrence. Although her initial presentation mimicked immune-mediated necrotizing myopathy (IMNM), the absence of myositis-specific antibodies and clinical improvement without immunosuppressive therapy supported a diagnosis of toxic rhabdomyolysis. This case highlights the importance of recognizing supplement-related toxicity and initiating timely organ-targeted supportive care. This appears to be the first reported case of RYR-induced rhabdomyolysis complicated by both AKI and respiratory failure from diaphragmatic dysfunction.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1634047"},"PeriodicalIF":3.1000,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12404951/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1634047","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Red yeast rice (RYR), a commonly used supplement with statin-like properties, is generally considered safe but may cause severe adverse effects such as rhabdomyolysis. We report a rare case of severe RYR-induced rhabdomyolysis complicated by acute kidney injury (AKI) and respiratory failure, with diaphragmatic dysfunction as a key contributing factor. A 78-year-old woman developed progressive proximal muscle weakness, dyspnea, and tea-colored urine after taking RYR (2 g/day) for 1 month. She rapidly progressed to respiratory failure requiring intubation and mechanical ventilation. Laboratory tests showed a peak creatine kinase (CK) of 112,985 U/L, serum myoglobin (>3,000 μg/L), and AKI. Bedside ultrasound demonstrated diaphragmatic dysfunction, while electromyography (EMG) revealed preserved nerve conduction. Myositis-specific and paraneoplastic antibody panels were negative. She received continuous renal replacement therapy (CRRT), plasma exchange (PE), hemoperfusion (HP), and supportive care. During hospitalization, she developed deep vein thrombosis (DVT), pneumonia, and ileus, all of which resolved with treatment. At discharge, she had been weaned from mechanical ventilation and had partially recovered renal and muscle function. At follow-up, she was stable, ambulating, and performing daily functions without symptom recurrence. Although her initial presentation mimicked immune-mediated necrotizing myopathy (IMNM), the absence of myositis-specific antibodies and clinical improvement without immunosuppressive therapy supported a diagnosis of toxic rhabdomyolysis. This case highlights the importance of recognizing supplement-related toxicity and initiating timely organ-targeted supportive care. This appears to be the first reported case of RYR-induced rhabdomyolysis complicated by both AKI and respiratory failure from diaphragmatic dysfunction.

Abstract Image

红曲米致严重横纹肌溶解合并急性肾损伤及呼吸衰竭1例。
红曲米(RYR)是一种常用的补充剂,具有类似他汀类药物的特性,通常被认为是安全的,但可能导致严重的不良反应,如横纹肌溶解。我们报告一例罕见的严重ryr诱导的横纹肌溶解合并急性肾损伤(AKI)和呼吸衰竭,膈功能障碍是一个关键因素。一位78岁女性在服用RYR (2 g/d) 1个月后出现进行性近端肌无力、呼吸困难和尿呈茶色。她迅速发展为呼吸衰竭,需要插管和机械通气。实验室检查显示肌酸激酶(CK)峰值为112,985 U/L,血清肌红蛋白(>3,000 μg/L), AKI。床边超声显示膈功能障碍,而肌电图显示保留神经传导。肌炎特异性抗体和副肿瘤抗体均为阴性。她接受了持续肾替代治疗(CRRT)、血浆置换(PE)、血液灌流(HP)和支持性治疗。住院期间,患者出现深静脉血栓、肺炎、肠梗阻,经治疗后均消失。出院时,患者已停用机械通气,肾脏和肌肉功能部分恢复。随访时,患者病情稳定,可行走,日常活动,无症状复发。虽然她最初的表现类似于免疫介导的坏死性肌病(IMNM),但缺乏肌炎特异性抗体和未经免疫抑制治疗的临床改善支持了中毒性横纹肌溶解的诊断。本病例强调了认识到补充剂相关毒性和及时启动器官靶向支持治疗的重要性。这似乎是第一例报道的ryr诱导的横纹肌溶解合并AKI和膈功能障碍引起的呼吸衰竭的病例。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Frontiers in Medicine
Frontiers in Medicine Medicine-General Medicine
CiteScore
5.10
自引率
5.10%
发文量
3710
审稿时长
12 weeks
期刊介绍: Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信